LR-90
Based on 1 Customer Validation
LR-90 is an advanced glycation end product (AGE) inhibitor, inhibits inflammatory responses in human monocytes. LR-90 is also used in the research of diabetic animal model.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.24%
- CAS 番号: 245075-84-7
- 分子式: C35H34Cl2N4O8
- 分子量:709.57
-
保管条件:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
-
Immunology/Inflammation Compound Library
HY-L007
-
Anti-Aging Compound Library
HY-L034
-
Anti-diabetic Compound Library
HY-L040
-
Ferroptosis Compound Library
HY-L051
-
Human Metabolite Library
HY-L123
-
Radioprotector Library
HY-L178
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Anti-Rheumatic Arthritis Compound Library
HY-L210
-
Mass Spectrometry Human Metabolite Library
HY-L215
生物活性
AGE[1]
LR-90 (0, 25, 50, 100, and 200 μM) inhibits RAGE, MCP-1, COX-2, IP-10 and NOX2 mRNA expression in THP-1 cells in a dose-dependent manner, after pretreatment 1 h befor S100b stimulatation for 4 hours[1].
LR-90 (0, 25, 50, 100, and 200 μM) dose-dependently and significantly blocks THP-1 cells adherence to endothelial cells after pretreatment 1 h befor S100b stimulatation for 24 hours[1].
LR-90 (0, 25, 50, 100, and 200 μM, for 24 hours) shows no effect on the cell viability of THP-1 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:THP-1 cells
-
Concentration:0, 25, 50, 100, and 200 μM
-
Incubation Time:24 hours
-
Result:Showed no cytotoxicity to THP-1 cells.
-
Cell Line:THP-1 cells
-
Concentration:0, 25, 50, 100, and 200 μM
-
Incubation Time:One hour before S100b addition for 4 hours
-
Result:Dose-dependently inhibited mRNA expression of RAGE, MCP-1, COX-2, IP-10, and NOX2 stimulated with S100b.
LR-90 (50 mg/L) decreases renal AGE, AGER and lipid peroxidation[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male ZDF rats (13 to 40 weeks)[2]
-
Dosage:50 mg/L
-
Administration:P.O. for 27 weeks
-
Result:Significantly reduced plasma triacylglycerol and cholesterol by ∼55% and ∼30%, respectively. Modestly affected hyperglycaemia and blood pressure. Lowered the body weight.
化学情報
-
CAS 番号 245075-84-7
-
性状 Solid
-
分子量 709.57
-
分子式 C35H34Cl2N4O8
-
Color White to off-white
-
SMILES
O=C(NC1=CC=C(C=C1)OC(C)(C)C(O)=O)NC(C(Cl)=C2)=CC=C2CC3=CC=C(C(Cl)=C3)NC(NC4=CC=C(C=C4)OC(C)(C)C(O)=O)=O
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
溶剤 & 溶解度
DMSO : ≥ 100 mg/mL (140.93 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (3.52 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
純度とドキュメンテーション
-
データシート (275 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Figarola JL, et al. Anti-inflammatory effects of the advanced glycation end product inhibitor LR-90 in human monocytes. Diabetes. 2007 Mar;56(3):647-55. [Content Brief]
[2]. Figarola JL, et al. LR-90 prevents dyslipidaemia and diabetic nephropathy in the Zucker diabetic fatty rat. Diabetologia. 2008 May;51(5):882-91. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.4093 mL | 7.0465 mL | 14.0930 mL | 35.2326 mL |
| 5 mM | 0.2819 mL | 1.4093 mL | 2.8186 mL | 7.0465 mL | |
| 10 mM | 0.1409 mL | 0.7047 mL | 1.4093 mL | 3.5233 mL | |
| 15 mM | 0.0940 mL | 0.4698 mL | 0.9395 mL | 2.3488 mL | |
| 20 mM | 0.0705 mL | 0.3523 mL | 0.7047 mL | 1.7616 mL | |
| 25 mM | 0.0564 mL | 0.2819 mL | 0.5637 mL | 1.4093 mL | |
| 30 mM | 0.0470 mL | 0.2349 mL | 0.4698 mL | 1.1744 mL | |
| 40 mM | 0.0352 mL | 0.1762 mL | 0.3523 mL | 0.8808 mL | |
| 50 mM | 0.0282 mL | 0.1409 mL | 0.2819 mL | 0.7047 mL | |
| 60 mM | 0.0235 mL | 0.1174 mL | 0.2349 mL | 0.5872 mL | |
| 80 mM | 0.0176 mL | 0.0881 mL | 0.1762 mL | 0.4404 mL | |
| 100 mM | 0.0141 mL | 0.0705 mL | 0.1409 mL | 0.3523 mL |
LR-90 関連分類
HY-76383 関連分類
Powered by Bioz